Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): Phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

Annals of Hematology

Volumn 93, Issue 6, 2014, Pages 965-975

  Willemze, R ^a   Suciu, S ^b   Muus, P ^c   Halkes, C J M ^a   Meloni, G ^d   Meert, L ^b   Karrasch, M ^b   Rapion, J ^b   Vignetti, M ^e   Amadori, S ^f   De Witte, T ^c   Marie, J P ^g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e GIMEMA Data Center   (Italy)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g HÔPITAL SAINT ANTOINE   (France)

Author keywords

Acute myeloid leukemia; Clofarabine; Phase I dose finding study

Indexed keywords

CLOFARABINE; CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG INTOXICATION; FATIGUE; FEMALE; HUMAN; HYPOPLASIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTOPENIA;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYDROXYUREA; HYPERBILIRUBINEMIA; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK; TREATMENT OUTCOME;

EID: 84902318385     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2056-6     Document Type: Article

References (22)

1. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G et al (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction an consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27:5397-5403
2. Willemze R, Suciu S,Meloni G, Labar B, Marie JP, Halkes CJ,Muus P et al (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMAAML-12 Trial. J Clin Oncol 32(3):219-228
3. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364(11):1027-1036
4. de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G et al (2010) Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 95(10):1754-1761
5. Burnett A,Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487-494
6. Kantarjian H, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J et al (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173 (Pubitemid 46594149)
7. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia- Manero G et al (2003) Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386 (Pubitemid 37193573)
8. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E et al (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940-947 (Pubitemid 40170859)
9. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian H et al (2005) The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 103:1985-1995, Review (Pubitemid 40605104)
10. Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S et al (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28:2389-2395
11. Cooper T, Ayres M, Nowak B, Gandhi V (2005) Biochemical modulation of cytarabine-triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361-368
12. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G et al (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51 (Pubitemid 43990611)
13. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638-1645
14. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F et al (2008) Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113:2090-2096
15. Kantarjian H, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T et al (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549-555
16. Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C et al (2011) Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 16: 197-206
17. Tse E, Leung AY, Sim J, Lee HK, Liu HS, Yip SF et al (2011) Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol 90: 1277-1281
18. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S et al (2011) Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 155:182-189
19. Faderl S, Ravandi F, HuangX,WangX, Jabbour E,Garcia-Manero G et al (2012) Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118:4471-4477
20. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 18-30
21. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
22. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649 (Pubitemid 46594039)